ICCC Immucell Corp.

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020

ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
EN
06/10/2020

Underlying

ICCCImmucell Corp.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immucell Corp.

 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell to Announce Unaudited Financial Results for the Quarter and Y...

ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025 Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ET PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a confere...

February 18, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Ful...

ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects...

January 8, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell to Conduct Conference Call with Investors to Discuss Strategi...

ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and awa...

January 7, 2026 1 EN
 PRESS RELEASE
Free
ICCC IMMUCELL CORP.

ImmuCell Announces Strategic Focus on First Defense® After Receiving a...

ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50...

December 24, 2025 1 EN
Free Trial
ICCC IMMUCELL CORP.

Immucell Corp: 1 director

A director at Immucell Corp maiden bought 9,738 shares at 5.092USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...

12/05/25 December 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch